MMJ net tangible asset value implies share price upside of 150%
Global cannabis investment group MMJ (ASX:MMJ) has released its March quarter business and investment update, a feature of which was the net tangible asset value per share as at March 31, 2020.
This highlighted that the company is trading at a sharp discount to its intrinsic value.
Similar to most players in the cannabis sector, MMJ’s share price has been sold down substantially in the last 12 months, but it needs to be remembered that it is a diversified operation that provides investment opportunities across the full range of emerging cannabis-related sectors, including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail.
Indeed, it is the only ASX listed investment company which offers Australian investors the opportunity to invest in unlisted and listed cannabis-related businesses in Australia and offshore.
Further, MMJ has a proven track record in acquiring and realising considerable value from its cannabis related investments.
Since 2015, MMJ has created a significant number of investment opportunities from its connections in Canada and Australia in the private investment sector and realised exits that have benefited its shareholders.
Consequently, it could be argued that MMJ doesn’t deserve the broadbrush treatment that has characterised the cannabis sector in the last 12 months or so.
Underlining the strength of MMJ’s investments is its net tangible asset value per share of approximately 20.5 cents, implying 150% share price upside relative to Wednesday’s closing price of 8.2 cents.
Learning from the wine and spirit industry
Management provided an interesting snapshot of dynamics within the cannabis industry and where it is heading.
Understanding these aspects is central to establishing a strategy that underpins investment in businesses that can provide optimal shareholder returns.
From a broader perspective MMJ is bullish on the economy as a whole going forward, but more importantly it is confident that it has cherry picked the winning sub-sectors in the cannabis space.
Consequently, management believes that it is now time to look for investment opportunities in a recovering market.
MMJ made an interesting analogy with other industries that have similar supply chains that span planting, harvesting, production, distribution and marketing.
On this note, management provided an overview of how the wine and spirits industry operates.
"The cannabis space is unique, but its product evolution is not likely to be that much more different from other social entertainment products such as wine and spirits. A farmer has to grow the various plants (grapes, potatoes, etc.) needed to produce different types of alcohol. The farmer then sells the biomass to a factory that in turn produces various consumer end products. These products are differentiated and marketed which in turn create long-term brand loyalty. In the case of wine, the farmer also creates the biomass and end product while simultaneously marketing and finding customers.
"However, the majority of revenue in the wine and spirits industry comes from the first type of arrangement and not the second. This is because farming isn’t a terribly attractive industry from a long-term growth perspective and therefore receives very little capital markets attention. In addition to being very capital intensive, growth in that industry is dependent on growing farm size and utilisation. Companies that purchase the biomass and turn it into consumer products however are far more attractive from a growth perspective and therefore capital markets perspective as well.
Putting the Bud into cannabis
Management is of the view that cannabis is superior to wine and spirits in terms of positive effect on the individual and on society as a whole, and its potential for secondary consumer branded products.
However, the plant to shelf cycle isn’t likely to evolve in a tremendously different way.
The cannabis industry in North America will likely have several large players and a lot of smaller specialty niche players.
Put simply, the majority of customers will consume the cannabis equivalent of Bud Light’s and Heineken’s while some of the enthusiasts will focus on smaller volume growers and niche brands.
Given these dynamics, it’s imperative not to own the farmers, but rather the processors and the consumer brands.
As indicated below, MMJ’s investment portfolio is skewed towards this industry sub-sector.
In fact, excess capital investment at bubble valuations into the farming sub-segment of the cannabis industry is what led to the overcapacity and collapse of the cannabis stocks in 2019.
MMJ, however, continues to be well-positioned in a recovery scenario through its focus on extraction and consumer branded products.
Impact on MMJ’s investment portfolio
Management explained that extraction is the engine that will drive higher margins in the cannabis space as it converts biomass into a variety of products that consumers perceive as being more value-add.
MMJ’s holdings in that space include Embark Health, Sequoya Cannabis, and Medipharm Labs.
On a combined basis, this sub-segment accounts for 39% of the group’s total portfolio.
After extraction the next engine of high margin growth will be Consumer Branded Products as they offer specific items on shelf that customers can rely on for consistent pricing and desired effect.
MMJ’s holdings in this sub-segment include Volero Brands, WeedMD, and Harvest One.
All told, CPG represents approximately 38% of the group’s total portfolio, and combined these two core cannabis 2.0 sub-segments represents almost 80% of its total portfolio.
While COVID-19 will cause an intermittent disruption, management is very bullish regarding the prospects of MMJ’s business investments.
In summing up, management said that the cannabis sector names that focus on extraction and consumer branded products will recover and lead the sector higher as the coronavirus disruption dissipates.
A key takeaway is that some companies have a disproportionate amount of capital tied up in cannabis farming, and these will seek to divest those capital-intensive assets and focus on higher margin extraction and consumer branded products.
Such cannabis 2.0 businesses will have higher valuations in the public markets as well.
This should provide MMJ’s private company holdings such as Embark Health and Sequoya Cannabis with the opportunity to become publicly listed entities, a development that would capture the intrinsic value of the businesses.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.